Retatrutide, a novel dual activator of the GLP-1 binding site and glucose-dependent insulinotropic polypeptide (GIP) target, is demonstrating promising outcomes in preliminary human trials . Ongoing https://icelisting.com/story22629540/retatrutide-emerging-research-and-projected-medical-uses